Tuberculosis of intestines, peritoneum and mesenteric glands
ICD-10 A18.3 is a used to indicate a diagnosis of tuberculosis of intestines, peritoneum and mesenteric glands.
Tuberculosis of the intestines, peritoneum, and mesenteric glands is a form of extrapulmonary tuberculosis that primarily affects the gastrointestinal tract. It is caused by Mycobacterium tuberculosis and can manifest as abdominal pain, diarrhea, weight loss, and fever. The disease can lead to complications such as intestinal obstruction or perforation. Diagnosis typically involves imaging studies like CT scans or ultrasounds, endoscopic evaluations, and microbiological tests such as stool cultures or biopsies. Treatment usually includes a multi-drug regimen over an extended period, often involving isoniazid, rifampicin, ethambutol, and pyrazinamide. Monitoring for drug resistance is crucial, as resistance can complicate treatment and prolong recovery. Public health implications are significant, as tuberculosis is a communicable disease, necessitating contact tracing and isolation procedures for active cases to prevent transmission.
Detailed patient history, diagnostic test results, treatment plans, and follow-up notes.
Patients presenting with abdominal symptoms and a history of tuberculosis exposure.
Consideration of drug resistance and the need for specialized treatment regimens.
Endoscopic findings, biopsy results, and imaging studies.
Patients with gastrointestinal symptoms and confirmed or suspected tuberculosis.
Differentiating between tuberculosis and other gastrointestinal disorders.
Used when evaluating gastrointestinal symptoms in suspected tuberculosis cases.
Document findings, biopsies taken, and any interventions performed.
Gastroenterologists should ensure thorough documentation of the procedure and findings.
Common symptoms include abdominal pain, diarrhea, weight loss, fever, and sometimes intestinal obstruction.
Diagnosis typically involves imaging studies, endoscopic evaluations, and microbiological tests such as stool cultures or biopsies.
Treatment usually involves a multi-drug regimen over an extended period, often including isoniazid, rifampicin, ethambutol, and pyrazinamide.
As a communicable disease, it necessitates contact tracing and isolation procedures for active cases to prevent transmission.
